2Jan De Beur SM,Levine MA.Molecular pathogenesis of hypophospliatemie rickets.J Clin Endocrinol Metab,2002,87:2467-2473.
3Folpe AL, Fanburg-smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologlc entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol, 2004,28:1-30.
4张孝骞.间叶瘤并发抗维生素D软骨病1例报告[J].中华医学杂志,1980,60:150-150.
5Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med, 2003,348 : 1656-1663.
6Huang QL, Feig DS, Blackstein ME. Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia. J Endocrinol Invest, 2000,23:263-267.
7Nelson AE, Bligh RC, Mirams M, et al. Clinical case seminar:Fibroblast growth facotor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab, 2003,88:4088-4094.
8Mc Murtry CT, Godschalk M, Maluche HH, et al. Oncogenic osteomalacia associated with metastatic prostate carcinoma: case report and review of the literature. J Am Geriatr Soc, 1993,41:983-985.
9Rhee Y, Lee JD, Shin KH, et al. Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clin Endocrinol (Oxf), 2001,54:551-554.
